Eucrates Biomedical Acquisition Corp. is a special purpose acquisition company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
Company profile
Ticker
EUCR, EUCRW
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
EUCR stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
8 May 23
25-NSE
Exchange delisting
26 Apr 23
10-K
2022 FY
Annual report
13 Apr 23
8-K
Eucrates Biomedical Acquisition Corp. Announces Liquidation
11 Apr 23
8-K
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
3 Apr 23
NT 10-K
Notice of late annual filing
29 Mar 23
8-K
Entry into a Material Definitive Agreement
16 Feb 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
8-K
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
8 Nov 22
8-K
Amendments to Articles of Incorporation or Bylaws
31 Oct 22
Latest ownership filings
SC 13G/A
Flynn James E
10 Feb 23
SC 13G
BlackRock Inc.
9 Nov 22
SC 13G
PRICE T ROWE ASSOCIATES INC /MD/
14 Feb 22
SC 13G/A
BlackRock Inc.
8 Feb 22
SC 13G
Eucrates LLC
12 Feb 21
SC 13G
BlackRock Inc.
8 Feb 21
4
PARAG SAXENA
27 Nov 20
4
STELIOS PAPADOPOULOS
27 Nov 20
4
Change in insider ownership
27 Nov 20
SC 13G
Flynn James E
30 Oct 20
Financial summary
Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 18.87 k | 18.87 k | 18.87 k | 18.87 k | 18.87 k | 18.87 k |
Cash burn (monthly) | 13.73 k | 2.52 k | 87.73 k | 58.21 k | (no burn) | 70.25 k |
Cash used (since last report) | 205.16 k | 37.73 k | 1.31 mm | 870.10 k | n/a | 1.05 mm |
Cash remaining | -186.29 k | -18.86 k | -1.29 mm | -851.23 k | n/a | -1.03 mm |
Runway (months of cash) | -13.6 | -7.5 | -14.7 | -14.6 | n/a | -14.7 |
Institutional ownership, Q4 2022
13F holders | Current |
---|---|
Total holders | 26 |
Opened positions | 24 |
Closed positions | 1 |
Increased positions | 0 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 1.11 bn |
Total shares | 4.28 mm |
Total puts | 0.00 |
Total calls | 26.73 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Eucrates | 2.62 mm | $26.33 mm |
Deerfield Management | 333.33 k | $18.53 mm |
683 Capital Management | 196.35 k | $10.92 mm |
Altium Capital Management | 133.33 k | $7.41 mm |
Granite Point Capital Management | 133.33 k | $7.08 mm |
Cowen And | 122.26 k | $6.80 mm |
Arena Investors | 94.52 k | $4.82 mm |
HealthCor Management | 78.06 k | $4.34 mm |
CVI | 74.08 k | $3.78 mm |
EcoR1 Capital | 66.67 k | $665.99 mm |